Translating ENIGMA schizophrenia findings using the regional vulnerability index: Association with cognition, symptoms, and disease trajectory

Patients with schizophrenia have patterns of brain deficits including reduced cortical thickness, subcortical gray matter volumes, and cerebral white matter integrity. We proposed the regional vulnerability index (RVI) to translate the results of Enhancing Neuro Imaging Genetics Meta‐Analysis studies to the individual level. We calculated RVIs for cortical, subcortical, and white matter measurements and a multimodality RVI. We evaluated RVI as a measure sensitive to schizophrenia‐specific neuroanatomical deficits and symptoms and studied the timeline of deficit formations in: early (≤5 years since diagnosis, N = 45, age = 28.8 ± 8.5); intermediate (6–20 years, N = 30, age 43.3 ± 8.6); and chronic (21+ years, N = 44, age = 52.5 ± 5.2) patients and healthy controls (N = 76, age = 38.6 ± 12.4). All RVIs were significantly elevated in patients compared to controls, with the multimodal RVI showing the largest effect size, followed by cortical, white matter and subcortical RVIs (d = 1.57, 1.23, 1.09, and 0.61, all p < 10−6). Multimodal RVI was significantly correlated with multiple cognitive variables including measures of visual learning, working memory and the total score of the MATRICS consensus cognitive battery, and with negative symptoms. The multimodality and white matter RVIs were significantly elevated in the intermediate and chronic versus early diagnosis group, consistent with ongoing progression. Cortical RVI was stable in the three disease‐duration groups, suggesting neurodevelopmental origins of cortical deficits. In summary, neuroanatomical deficits in schizophrenia affect the entire brain; the heterochronicity of their appearance indicates both the neurodevelopmental and progressive nature of this illness. These deficit patterns may be useful for early diagnosis and as quantitative targets for more effective treatment strategies aiming to alter these neuroanatomical deficit patterns.

[1]  Emily L. Dennis,et al.  ENIGMA‐DTI: Translating reproducible white matter deficits into personalized vulnerability metrics in cross‐diagnostic psychiatric research , 2020, Human brain mapping.

[2]  Yogesh Rathi,et al.  White matter abnormalities across the lifespan of schizophrenia: a harmonized multi-site diffusion MRI study , 2019, Molecular Psychiatry.

[3]  N. Jahanshad,et al.  White Matter in Schizophrenia Treatment Resistance. , 2019, The American journal of psychiatry.

[4]  P. Thompson,et al.  Toward High Reproducibility and Accountable Heterogeneity in Schizophrenia Research. , 2019, JAMA psychiatry.

[5]  Adrian Preda,et al.  Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium , 2018, Biological Psychiatry.

[6]  Dan J Stein,et al.  Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group , 2017, Molecular Psychiatry.

[7]  I. Melle,et al.  Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium , 2016, Molecular Psychiatry.

[8]  S. Leucht,et al.  Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. , 2016, JAMA psychiatry.

[9]  I. Melle,et al.  Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium , 2015, Molecular Psychiatry.

[10]  T. Schulze,et al.  Kraepelin revisited: schizophrenia from degeneration to failed regeneration , 2015, Molecular Psychiatry.

[11]  P. Kochunov,et al.  Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. , 2014, Schizophrenia bulletin.

[12]  P. Fitzgerald,et al.  Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age , 2014, Molecular Psychiatry.

[13]  Paul M. Thompson,et al.  Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: A pilot project of the ENIGMA–DTI working group , 2013, NeuroImage.

[14]  S K Holland,et al.  DTI Values in Key White Matter Tracts from Infancy through Adolescence , 2013, American Journal of Neuroradiology.

[15]  J N Giedd,et al.  Neurodevelopmental model of schizophrenia: update 2012 , 2012, Molecular Psychiatry.

[16]  D. Glahn,et al.  Fractional anisotropy of water diffusion in cerebral white matter across the lifespan , 2012, Neurobiology of Aging.

[17]  T. McGlashan Eugen Bleuler: centennial anniversary of his 1911 publication of Dementia Praecox or the group of schizophrenias. , 2011, Schizophrenia bulletin.

[18]  P. Fox,et al.  Fractional anisotropy of cerebral white matter and thickness of cortical gray matter across the lifespan , 2011, NeuroImage.

[19]  Paul M. Thompson,et al.  Genetic Analysis of Cortical Thickness and Fractional Anisotropy of Water Diffusion in the Brain , 2011, Front. Neurosci..

[20]  Gert Cauwenberghs,et al.  Neuromorphic Silicon Neuron Circuits , 2011, Front. Neurosci.

[21]  D. Jeste,et al.  Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. , 2011, Schizophrenia bulletin.

[22]  Uniwersytet Jagielloński,et al.  The Concept , 2010, The Knights Templar.

[23]  A. David,et al.  Processing speed deficits in schizophrenia: reexamining the evidence. , 2010, The American journal of psychiatry.

[24]  Kelvin O. Lim,et al.  Hybrid ICA-Seed-Based Methods for fMRI Functional Connectivity Assessment: A Feasibility Study , 2010, Int. J. Biomed. Imaging.

[25]  T. Salthouse When does age-related cognitive decline begin? , 2009, Neurobiology of Aging.

[26]  Shu-ping Tan,et al.  Clinical reliability and validity of the Chinese version of Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery , 2009 .

[27]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. , 2008, The American journal of psychiatry.

[28]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. , 2008, The American journal of psychiatry.

[29]  J. Gold,et al.  Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. , 2007, Archives of general psychiatry.

[30]  A. Addington,et al.  The neurodevelopmental model of schizophrenia: update 2005 , 2005, Molecular Psychiatry.

[31]  Margaret P. Poe,et al.  Defining a cognitive function decrement in schizophrenia , 2005, Biological Psychiatry.

[32]  Philip D. Harvey,et al.  The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery , 2004, Schizophrenia Research.

[33]  Thomas F. Nugent,et al.  Dynamic mapping of human cortical development during childhood through early adulthood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Suzanne E. Welcome,et al.  Mapping cortical change across the human life span , 2003, Nature Neuroscience.

[35]  D. Javitt,et al.  Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. , 2002, The American journal of psychiatry.

[36]  Larry J Seidman,et al.  Neuropsychologic functioning among the nonpsychotic relatives of schizophrenic patients: the effect of genetic loading , 2000, Biological Psychiatry.

[37]  Adityanjee,et al.  Dementia praecox to schizophrenia: The first 100 years , 1999, Psychiatry and clinical neurosciences.

[38]  Daniel R. Weinberger,et al.  Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.

[39]  R. Murray,et al.  A neurodevelopmental approach to the classification of schizophrenia. , 1992, Schizophrenia bulletin.

[40]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[41]  E. Bleuler [Dementia praecox or the group of schizophrenias]. , 1968, Vertex.

[42]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[43]  D. Charney,et al.  Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.

[44]  Alexander L. Miller,et al.  Practice guideline for the treatment of patients with schizophrenia, second edition. , 2004, The American journal of psychiatry.

[45]  John H Krystal,et al.  Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. , 2003, Archives of general psychiatry.

[46]  David A Lewis,et al.  Schizophrenia as a disorder of neurodevelopment. , 2002, Annual review of neuroscience.

[47]  J. Knoll,et al.  Heterogeneity of the psychoses: is there a neurodegenerative psychosis? , 1998, Schizophrenia bulletin.

[48]  R. McCarley,et al.  Progressive changes in schizophrenia: do they exist and what do they mean? , 1998, Restorative neurology and neuroscience.

[49]  Julie Kreyenbuhl,et al.  Practice guideline for the treatment of patients with schizophrenia , 1997 .

[50]  I. Feinberg,et al.  Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? , 1982, Journal of psychiatric research.

[51]  Christian Beaulieu Published online in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/nbm.782 Review Article , 2022 .